Giorgio Walter Canonica , 1 , Linda Cox 2 , Ruby Pawankar 3 , Carlos E Baena-Cagnani 4 , Michael Blaiss 5 , Sergio Bonini 6 , Jean Bousquet 7 , Moises Calderón 8 , Enrico Compalati 9 , Stephen R Durham 10 , Roy Gerth van Wijk 11 , Désirée Larenas-Linnemann 12 , Harold Nelson 13 , Giovanni Passalacqua 14 , Oliver Pfaar 15 , Nelson Rosário 16 , Dermot Ryan 17 , Lanny Rosenwasser 18 , Peter Schmid-Grendelmeier 19 , Gianenrico Senna 20 , Erkka Valovirta 22 , Hugo Van Bever 21 , Pakit Vichyanond 23 , Ulrich Wahn 24 , Osman Yusuf 25
28 March 2014
We have prepared this document, “Sublingual Immunotherapy: World Allergy Organization Position Paper 2013 Update”, according to the evidence-based criteria, revising and updating chapters of the originally published paper, “Sublingual Immunotherapy: World Allergy Organization Position Paper 2009”, available at http://www.waojournal.org. Namely, these comprise: “Mechanisms of sublingual immunotherapy;” “Clinical efficacy of sublingual immunotherapy” – reporting all the data of all controlled trials published after 2009; “Safety of sublingual immunotherapy” – with the recently published Grading System for adverse reactions; “Impact of sublingual immunotherapy on the natural history of respiratory allergy” – with the relevant evidences published since 2009; “Efficacy of SLIT in children” – with detailed analysis of all the studies; “Definition of SLIT patient selection” – reporting the criteria for eligibility to sublingual immunotherapy; “The future of immunotherapy in the community care setting”; “Methodology of clinical trials according to the current scientific and regulatory standards”; and “Guideline development: from evidence-based medicine to patients' views” – including the evolution of the methods to make clinical recommendations.
Additionally, we have added new chapters to cover a few emerging crucial topics: “Practical aspects of schedules and dosages and counseling for adherence” – which is crucial in clinical practice for all treatments; “Perspectives and new approaches” – including recombinant allergens, adjuvants, modified allergens, and the concept of validity of the single products. Furthermore, “Raising public awareness about sublingual immunotherapy”, as a need for our patients, and strategies to increase awareness of allergen immunotherapy (AIT) among patients, the medical community, all healthcare stakeholders, and public opinion, are also reported in detail.